Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(3S,4S)-3-[([4-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-3-[([4-[(2-ethyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-3-[([4-[(2-ethylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-3-[([4-[(2-tert-butylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[([4-[(2-methylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | substance exhibits excellent oral bioavailability in pharmacokinetic studies | Sus scrofa | |
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide | - |
Sus scrofa | |
(3S,4S)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]pyrrolidine-3-carboxamide | - |
Sus scrofa |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Sus scrofa | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
blood | cellular suppression of TNF-alpha is measured using human whole blood (WBA) stimulated with lipopolysaccharide (LPS) | Sus scrofa | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
TNF-alpha + H2O | - |
Sus scrofa | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
TACE | - |
Sus scrofa |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.000001 | - |
(3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | - |
Sus scrofa |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.000001 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | |
0.000001 | - |
- |
Sus scrofa | (3S,4S)-3-[([4-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | |
0.000001 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[([4-[(2-methylimidazo[1,2-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide | |
0.000001 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide | |
0.000001 | - |
- |
Sus scrofa | (3S,4S)-3-[([4-[(2-ethyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | |
0.000001 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]-1-prop-2-yn-1-ylpyrrolidine-3-carboxamide | |
0.0000015 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[[(4-[[2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | |
0.0000016 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1-benzofuran-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide | |
0.0000017 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | |
0.0000018 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-4-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]pyrrolidine-3-carboxamide | |
0.000002 | - |
- |
Sus scrofa | (3S,4S)-3-[([4-[(2-ethylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | |
0.0000021 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)-1-benzofuran-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | |
0.0000022 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-4-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]pyrrolidine-3-carboxamide | |
0.0000028 | - |
- |
Sus scrofa | (3S,4S)-3-[([4-[(2-tert-butylpyrazolo[1,5-a]pyridin-3-yl)methyl]phenyl]carbonyl)amino]-N-hydroxytetrahydro-2H-pyran-4-carboxamide | |
0.0000032 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[[(4-[[2-(1-methylethyl)imidazo[1,2-a]pyridin-3-yl]methyl]phenyl)carbonyl]amino]tetrahydro-2H-pyran-4-carboxamide | |
0.000006 | - |
- |
Sus scrofa | (3S,4S)-N-hydroxy-3-[([4-[(2-methyl-1H-indol-3-yl)methyl]phenyl]carbonyl)amino]tetrahydro-2H-pyran-4-carboxamide |